RBM4

Across TCGA pan-cancer cohorts, RBM4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RBM4 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBM4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBM4 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where RBM4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.906	1.000	.006	23	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.868	.016	12	view →
PDAC	OS	Median	II,III,IV	0.295	0.443	.026	6	view →
UCEC	DFS	Quartile	III,IV	1.000	0.379	.040	4	view →
CCRCC	OS	Median	II,III,IV	0.422	1.000	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RBM4–HNSC (DFS)

Open the HNSC breakdown →